Altimmune’s (ALT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT) in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a $12.00 price target on the stock. HC Wainwright also issued estimates for Altimmune’s FY2029 earnings at $1.26 EPS.

Several other brokerages also recently weighed in on ALT. William Blair started coverage on Altimmune in a research report on Friday, February 28th. They issued a “market perform” rating for the company. Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. Finally, UBS Group started coverage on Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target for the company. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $20.83.

Altimmune Price Performance

Shares of NASDAQ ALT opened at $5.72 on Monday. Altimmune has a 1-year low of $5.28 and a 1-year high of $11.77. The business has a 50-day moving average of $6.74 and a 200-day moving average of $7.18. The company has a market capitalization of $440.52 million, a price-to-earnings ratio of -3.69 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Research analysts expect that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Ameriprise Financial Inc. lifted its holdings in Altimmune by 35.6% during the 4th quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock worth $37,888,000 after buying an additional 1,378,854 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Altimmune by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after buying an additional 74,194 shares during the last quarter. Bellevue Group AG lifted its holdings in Altimmune by 9.5% during the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock worth $6,817,000 after buying an additional 81,786 shares during the last quarter. Northern Trust Corp lifted its holdings in Altimmune by 5.7% during the 4th quarter. Northern Trust Corp now owns 665,916 shares of the company’s stock worth $4,801,000 after buying an additional 35,918 shares during the last quarter. Finally, Two Sigma Investments LP lifted its holdings in Altimmune by 33.2% during the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock worth $4,364,000 after buying an additional 151,001 shares during the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.